Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Nasal ObstructionChronic Rhinitis
Interventions
DRUG

Oxymetazoline + Triamcinolone

"Participants will be stratified according to this usage and placed into a titration schedule.~* Titration 1: 0.05% 5x/day,~* Titration 2: 0.05% 4x/day,~* Titration 3: 0.05 3x/day,~* Titration 4: 0.05% 2x/day.~Participants with twice daily use, will then be placed in a titration schedule for oxymetazoline concentration which will stop when the oxymetazoline concentration is set to zero.~* Titration 5: 0.0375% Afrin/Nasacort 2x/day,~* Titration 6: 0.025% Afrin/Nasacort 2x/day,~* Titration 7: 0.0125% Afrin/Nasacort 2x/day,~* Titration 8: 0.0% Afrin/Nasacort 2x/day."

Trial Locations (1)

63110

RECRUITING

Washington University, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT07168148 - Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants | Biotech Hunter | Biotech Hunter